« Return to News | CROs/Service Providers

AMRI announces additional actions to streamline operations

Monday, January 9, 2012 01:40 PM

Albany Molecular Research (AMRI) took steps in the fourth quarter of 2011 to align the business to current and expected market conditions, including reducing the company’s workforce, right size capacity and reduce operating costs for 2012.

The workforce reduction primarily affects personnel based in AMRI’s U.S. operations and includes positions associated with R&D. The decision to wind down all R&D activities was announced in November 2011.

AMRI also will be terminating a lease of one of its U.S. facilities, reducing annual operating expenses. The company expects these actions will result in annuals savings approximating $10-11 million (including $7 million relating to the cessation of R&D activities). Savings are expected to be reflected in the first quarter of 2012.

“As we stated in our announcement in November, we are committed to taking the necessary actions to reduce the company’s operating expenses to focus on our core contract research and manufacturing business and to ensure profitability,” said Thomas E. D’Ambra , AMRI president, CEO and chairman. “These actions will place AMRI in a more cost-competitive position while ensuring we continue to provide the highest quality service to our clients.”

In addition, AMRI filed a shelf registration statement with the Securities and Exchange Commission, which, once effective, will allow AMRI to offer its common stock, preferred stock and warrants at an aggregate public offering price of up to $50 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.